{
    "address": "Virdings Alle 32 B",
    "city": "Uppsala",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W56164101",
    "description": "LIDDS AB develops pharmaceutical products for cancer and other diseases with NanoZolid technology. The company is headquartered in Uppsala, Uppsala and currently employs 3 full-time employees. The company went IPO on 2014-07-31. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. The company targets primarily solid tumors. The Company\u2019s portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.",
    "employeeTotal": "3.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2014-07-31",
    "isin": "SE0001958612",
    "logo": "https://finnhub.io/api/logo?symbol=LIDDS.ST",
    "marketCapitalization": 478.5763,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Lidds AB",
    "phone": "4600445566.0",
    "sedol": "B6SDXN6",
    "shareOutstanding": 29.675316,
    "state": "UPPSALA",
    "ticker": "LIDDS.ST",
    "weburl": "http://www.lidds.se/"
}